---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-006"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-006. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 23 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/vx20-147-006"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-006

<a id="heading-3.1.7"></a>

## 3.1.7 VX20-147-006

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Purpose stated in the registry record

> “The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.1-2"></a>

#### Aim stated in the congress abstract

> “We evaluated the pharmacokinetics (PK) of IXP in participants with renal or hepatic impairment compared to the PK in matched healthy participants in 2 separate studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2024-08-02” |
| Primary completion (actual) | “2024-12-20” |
| Study completion (actual) | “2024-12-20” |
| First posted | “2024-07-31” |
| Last update posted | “2025-01-20” |
| Other study ID numbers | “VX20-147-006” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.2-2"></a>

#### Study locations in the registry record

> “This study has 3 locations”
> “Miami, Florida, United States, 33136”
> “St. Petersburg, Florida, United States, 33705”
> “San Antonio, Texas, United States, 78215”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.2-3"></a>

#### Presentation at the NKF 2026 Spring Clinical Meetings

> “NKF 2026 Spring Clinical Meetings Abstracts”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Phase 1, open-label, single-dose design with matched healthy participants

> “A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.3-2"></a>

#### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.3-3"></a>

#### Comparison with matched healthy participants

> “We compared systemic exposures of IXP to matched healthy participants using geometric least squares mean ratios (GLSMR).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Child-Pugh classes and matching of healthy participants

> “Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A)”
> “Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B)”
> “Participants will be matched during screening to participants with mild (Cohort 1) or moderate (Cohort 3) hepatic impairment according to each of the following parameters: age (± 10 years); sex; and BMI (± 15%)”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.4-2"></a>

#### Key exclusion criteria in the registry record

> “Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug”
> “Participants who smoke”
> “Any condition possibly affecting drug absorption”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.4-3"></a>

#### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 75 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Single 45 mg oral dose

> “evaluated the PK and safety of IXP following a single 45-mg oral dose”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.5-2"></a>

#### Arms in the registry record

> “Experimental: Cohort 1: Mild Hepatic Impairment”
> “Experimental: Cohort 2: Matched Healthy Participants”
> “Experimental: Cohort 3: Moderate Hepatic Impairment”
> “Experimental: Cohort 4: Matched Healthy Participants”
> “Tablet for oral administration.”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Plasma Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.7.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of IXP” | “From Day 1 up to Day 10” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP” | “From Day 1 up to Day 10” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “From Day 1 up to Day 20” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.6.1-2"></a>

##### Hepatic metabolism as the primary elimination pathway

> “IXP primarily undergoes hepatic metabolism, while renal clearance represents a minor pathway.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “36” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.7.1-2"></a>

##### Enrollment reported in the congress abstract

> “36 participants were enrolled in the hepatic study”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Exposure in mild or moderate hepatic impairment compared with healthy matches

> “There were no clinically meaningful differences observed in participants with mild (N=10) or moderate (N=10) hepatic impairment compared to their healthy matches (N=16; GLSMR <125%).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.8.3-2"></a>

##### Higher exposure in one participant with a Child-Pugh score of 9

> “One participant with a CP score of 9 had approximately a 2.2-fold higher AUC compared to participants with a CP score of 7 or below, suggesting a potential effect on IXP systemic exposure in the hepatically impaired participant with a CP score of 9.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.8.3-3"></a>

##### Conclusion on dose adjustment

> “No clinically meaningful differences in IXP PK were observed in patients with renal impairment or with mild to moderate hepatic impairment up to and including a CP score of 7. Therefore, no dose adjustment of IXP is anticipated in these populations.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Safety in the renal and hepatic impairment studies

> “IXP was generally safe and well tolerated in both studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary: study limitations

VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796); [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.9-2"></a>

#### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
